Previously headquartered in PA and now re-located in Rockville, MD, Immunomic Therapeutics, Inc. (ITI) is a clinical-stage biotechnology company developing next-generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. The company's LAMP-Vax vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.
